Mizuho Maintains Neutral on Tandem Diabetes Care, Lowers Price Target to $20

Benzinga Newsdesk www.benzinga.com Negative 64.3%

Neg 64.3% Neu 0% Pos 0%

Mizuho analyst Anthony Petrone maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Neutral and lowers the price target from $24 to $20.